Pharmacology Unit, Biomedical Sciences Department, University of Alcalá, Alcalá de Henares, 28805 Madrid, Spain.
Department of Medicine and Medical Specialties, Faculty of Medicine and Health Sciences, University of Alcalá, Alcalá de Henares, 28801 Madrid, Spain.
Molecules. 2022 Feb 8;27(3):1146. doi: 10.3390/molecules27031146.
Flavonoids are compounds with a benzopyranic structure that exhibits multiple pharmacological activities. They are known for their venotonic activity, but their mechanism of action remains unclear. It is thought that, as this mechanism is mediated by prostaglandins, these compounds may interfere with the arachidonic acid (AA) cascade. These assays are designed to measure the antiplatelet aggregation capacity of quercetin, rutin, diosmetin, diosmin, and hidrosmin, as well as to evaluate a potential structure-activity ratio. In this paper, several studies on platelet aggregation at different concentrations (from 0.33 mM to 1.5 mM) of different flavone compounds are conducted, measuring platelet aggregation by impedance aggregometry, and the cyclooxygenase (COX) activity by metabolites generated, including the activity of the pure recombinant enzyme in the presence of these polyphenols. The results obtained showed that quercetin and diosmetin aglycones have a greater antiplatelet effect and inhibit the COX enzyme activity to a greater extent than their heterosides; however, the fact that greater inhibition of the pure recombinant enzyme was achieved by heterosides suggests that these compounds may have difficulty in crossing biological membranes. In any case, in view of the results obtained, it can be concluded that flavonoids could be useful as coadjuvants in the treatment of cardiovascular pathologies.
类黄酮是具有苯并吡喃结构的化合物,具有多种药理活性。它们以静脉张力活性而闻名,但作用机制尚不清楚。据认为,由于这种机制是由前列腺素介导的,这些化合物可能会干扰花生四烯酸(AA)级联。这些测定旨在测量槲皮素、芦丁、香叶木素、橙皮苷和香叶木苷的抗血小板聚集能力,并评估潜在的结构-活性比。在本文中,研究了不同浓度(从 0.33mM 到 1.5mM)的不同类黄酮化合物对血小板聚集的影响,通过阻抗聚集度测定法测量血小板聚集,通过代谢物生成来评估环氧化酶(COX)活性,包括在这些多酚存在下纯重组酶的活性。结果表明,槲皮素和香叶木苷苷元具有更强的抗血小板作用,对 COX 酶活性的抑制作用更强,但其糖苷的抑制作用更强,这表明这些化合物可能难以穿过生物膜。无论如何,鉴于所获得的结果,可以得出结论,类黄酮可用作治疗心血管病理的辅助剂。
Molecules. 2022-2-8
Molecules. 2021-5-19
Int J Mol Sci. 2021-6-25
Biomed Pharmacother. 2021-9
Int J Mol Sci. 2024-1-26
Front Cardiovasc Med. 2023-11-16
Front Cell Dev Biol. 2022-4-6
Eur J Drug Metab Pharmacokinet. 2022-1
Clin Appl Thromb Hemost. 2021
Biomed Pharmacother. 2021-9
Molecules. 2021-5-19
Molecules. 2020-11-30
Cochrane Database Syst Rev. 2020-11-3